Kaliumchlorid B. Braun

Potassium chloride, the active ingredient in Kaliumchlorid B. Braun, is an electrolyte presented as an injectable solution for intravenous use. It is employed to correct low serum potassium levels (hypokalemia) and to provide potassium supplementation during intravenous therapy in hospitalized patients requiring electrolyte management.

GNH USA supplies Kaliumchlorid B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide, ensuring quality‑assured products sourced from the EU market, with reliable logistics and regulatory support for global distribution.

Kaliumchlorid B. Braun, an intravenous potassium chloride solution, is used to manage disorders of potassium balance. - Hypokalemia: Restores normal serum potassium concentrations in patients with low potassium levels. - Post‑operative care: Provides potassium replacement to support cellular function after surgery. - Diuretic therapy: Compensates for potassium loss associated with loop or thiazide diuretics. - Dialysis patients: Supplies potassium to maintain electrolyte balance during or after renal replacement therapy. - Severe burns: Replenishes potassium lost through fluid shifts in burn patients.

Intravenous potassium chloride may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: Discomfort or burning at the infusion site. - Nausea: Mild gastrointestinal upset. - Transient hyperkalemia: Temporary rise in serum potassium that resolves with monitoring. - Muscle weakness: Mild, reversible reduction in muscle strength.

Serious or Rare Side Effects: - Cardiac arrhythmia: Potential for life‑threatening rhythm disturbances. - Severe hyperkalemia: Marked elevation of serum potassium leading to cardiac arrest. - Venous thrombosis: Clot formation at the catheter site. - Anaphylactoid reaction: Rare hypersensitivity with hypotension and respiratory distress.

When using Kaliumchlorid B. Braun, clinicians should observe several safety measures to minimize risks. - Patient assessment: Verify serum potassium levels and renal function before administration. - Infusion rate: Administer slowly, typically not exceeding 10‑20 mmol per hour, to avoid rapid serum changes. - Cardiac monitoring: Observe ECG for arrhythmias during and after infusion. - Drug compatibility: Do not mix with calcium or bicarbonate solutions unless compatibility is confirmed. - Contraindications: Avoid use in patients with hyperkalemia, severe renal impairment, or digitalis toxicity. - Store at 2‑8 °C: Keep refrigerated, protect from light, do not freeze or shake.

Potassium chloride can interact with several medications, altering potassium balance or cardiac safety.

Major Interactions (Avoid): - ACE inhibitors: May increase serum potassium, risking hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): Additive potassium elevation. - NSAIDs: Reduce renal potassium excretion, enhancing hyperkalemia risk. - Digoxin: Hyperkalemia heightens digoxin toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: May mask symptoms of hyperkalemia. - Insulin or glucose infusion: Can shift potassium intracellularly, affecting serum levels. - Corticosteroids: May cause potassium loss, requiring dose adjustment.